AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34786087
Drug: OCT-guided drug
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT-guided drug coated balloon (DCB)
Trial: 34786477
Drug: Nilotinib, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib, 300 mg
Trial: 34786477
Drug: Nilotinib, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib, 150 mg
Trial: 34786649
Drug: L-Ornithine phenylacetate
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Ornithine phenylacetate
Trial: 34786667
Drug: Peptide p5+14
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide p5+14 radiolabeled with iodine-124, single intravenous infusion
Trial: 34787590
Drug: Automated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated treatment (AT)
Trial: 34788228
Drug: Cosyntropin infusion
RxNorm normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cosyntropin infusion (ACTH(1-24))
Trial: 34788228
Drug: Cosyntropin infusion
RxNorm normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cosyntropin infusion
Trial: 34788401
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH)
Trial: 34788506
Drug: Autologous hematopoietic
RxNorm normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with an α-L-iduronidase (IDUA)-encoding lentiviral vector after myeloablative conditioning
Trial: 34789156
Drug: Plasma soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma soluble urokinase plasminogen activator receptor (suPAR) levels ≥ 14.7 ng/mL
Trial: 34789304
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of highly malignant or malignant EEG pattern with background frequency of delta waves or undetermined
Trial: 34789490
Drug: Serology for
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serology for SARS-CoV-2 IgG antibodies introduced in 2020
Trial: 34789494
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly singing sessions facilitated by Breathe Arts Health Research
Trial: 34789774
Drug: Deep learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning (DL) network for predicting early on-treatment response in mCRC.
Trial: 34789774
Drug: Size-based methodology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size-based methodology for predicting early on-treatment response in mCRC.
Trial: 34790261
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy
Trial: 34790348
Drug: Seralutinib (inhaled),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seralutinib (inhaled), administered for 24 weeks
Trial: 34790348
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered for 24 weeks
Trial: 34790371
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg once daily) plus S-1 (40-60 mg twice daily on days 1-14)
Trial: 34791634
Drug: Conventional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Trial: 34791755
Drug: Novel low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Novel low-dose paclitaxel-coated balloon with citrate-based excipient (Agent PCB)
Trial: 34792107
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (CAPOX)
Trial: 34792477
Drug: Teleassessments using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teleassessments using a computer tablet and testing equipment shipped to participants' homes
Trial: 34792559
Drug: Nicotinamide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1000 to 3000 mg) and pyruvate (1500 to 3000 mg)
Trial: 34793256
Drug: Venetoclax (dose-escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (dose-escalated from 200 mg to a maximum of 800 mg daily for up to 2 years)
Trial: 34793505
Drug: WRSs2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSs2 vaccine
Trial: 34793505
Drug: WRSs3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSs3 vaccine
Trial: 34793505
Drug: WRSs2 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WRSs2 and WRSs3 vaccines
Trial: 34793719
Drug: Single-agent evorpacept
RxNorm normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent evorpacept (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg once per week; 30 mg/kg once every other week)
Trial: 34793719
Drug: Evorpacept plus
RxNorm normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evorpacept plus pembrolizumab (200 mg every 3 weeks)
Trial: 34793719
Drug: Evorpacept plus
RxNorm normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evorpacept plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks)
Trial: 34793719
Drug: Evorpacept (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evorpacept (30 mg/kg once every other week)
Trial: 34793719
Drug: Evorpacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evorpacept (10 mg/kg once per week)
Trial: 34793923
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plaque features (matrix, intraplaque hemorrhage [IPH], wall thickness, plaque burden) and clinical features (age, body mass index, lipid levels)
Trial: 34794396
Drug: neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy with liposomal irinotecan (nal-IRI), oxaliplatin (OX), and 5-fluouracil/folinic acid (FA) (NAPOX)
Trial: 34794420
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) starting dosage 30 mg/kg/day in 6 hours
Trial: 34794989
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy with androgen deprivation therapy (ADT) and intensification with agents such as docetaxel, abiraterone acetate, and enzalutamide.
Trial: 34794989
Drug: Local cytoreductive
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local cytoreductive approaches (external beam radiotherapy, cytoreductive radical prostatectomy, or minimally invasive ablative therapy) and metastases-directed therapies (metastasectomy or stereotactic ablative body radiotherapy).
Trial: 34795408
Drug: Pamiparib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib (60 mg BID, RP2D; 80 mg BID, MTD)
Trial: 34795408
Drug: Pamiparib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib (80 mg BID)
Trial: 34795408
Drug: Pamiparib (dose-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib (dose-escalation phase)
Trial: 34795912
Drug: Combination pemetrexed-cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination pemetrexed-cisplatin chemoradiotherapy
Trial: 34796395
Drug: Increased parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased parent and self-identification of medication barriers (per 1 point)
Trial: 34797221
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin administered at 3 mL/kg by intravenous infusion over 30 minutes
Trial: 34797307
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test in FM patients
Trial: 34799399
Drug: NIZ985 (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIZ985 (0.25, 0.5, 1, 2 or 4 µg/kg subcutaneous TIW for the first 2 weeks of each 28-day cycle)
Trial: 34800109
Drug: Isatuximab in
RxNorm normalized name: isatuximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab in combination with pomalidomide plus dexamethasone
Trial: 34800167
Drug: Myasthenia gravis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myasthenia gravis patients (MG)
Trial: 34800279
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for cardioembolic LVO (CE-LVO)
Trial: 34800279
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for other stroke subtypes
Trial: 34800495
Drug: Photobiomodulation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation Therapy (FBMT)
Trial: 34800678
Drug: Vibostolimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibostolimab monotherapy (2.1-700 mg)
Trial: 34800678
Drug: Vibostolimab plus
RxNorm normalized name: Vibostolimab
DrugBank: Vibostolimab (DB16420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibostolimab plus pembrolizumab (200 mg) combination therapy
Trial: 34800678
Drug: Vibostolimab plus
RxNorm normalized name: Vibostolimab
DrugBank: Vibostolimab (DB16420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-naive NSCLC
Trial: 34800678
Drug: Vibostolimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibostolimab monotherapy in anti-PD-1/PD-L1-refractory NSCLC
Trial: 34800678
Drug: Vibostolimab plus
RxNorm normalized name: Vibostolimab
DrugBank: Vibostolimab (DB16420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-refractory NSCLC
Trial: 34800988
Drug: Postoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative physical therapy
Trial: 34801015
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (calcium and active vitamin D)
Trial: 34801051
Drug: Weifuchun (WFC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weifuchun (WFC) tablets, 1.44 g three times a day for 6 months
Trial: 34801051
Drug: Vitacoenzyme (Vit)
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitacoenzyme (Vit) tablets, 0.8 g three times a day for 6 months
Trial: 34801051
Drug: WFC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WFC treatment
Trial: 34801354
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2a)
Trial: 34801354
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL2)
Trial: 34801354
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL1)
Trial: 34801354
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2b)
Trial: 34801354
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL1)
Trial: 34801735
Drug: ECG patch
RxNorm normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECG patch monitoring pre-, immediately post-, and 2-3 months post-TAVR
Trial: 34801735
Drug: ECG patch
RxNorm normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECG patch monitoring
Trial: 34801749
Drug: Aumolertinib (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aumolertinib (110 mg orally once daily)
Trial: 34802427
Drug: Flexible and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible and integrated treatment (FIT) model project at the model hospital
Trial: 34802455
Drug: Permethrin-treated uniform
RxNorm normalized name: Permethrin
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permethrin-treated uniform with placebo lotion
Trial: 34802455
Drug: Untreated uniforms
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated uniforms with placebo lotion
Trial: 34802792
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine (first dose)
Trial: 34802792
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine (second dose)
Trial: 34802864
Drug: Nivolumab 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 360 mg and docetaxel 75 mg/m²
Trial: 34802966
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg initiated, average dose 45.5 mg/day)
Trial: 34802966
Drug: Cabozantinib (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (treatment line subgroups)
Trial: 34803851
Drug: Enhancing left
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhancing left beta/theta power ratio NF training in combination with reducing right beta/theta power ratio NF training
Trial: 34804358
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 100mg once daily
Trial: 34804608
Drug: Metformin-inclusive sulfonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-inclusive sulfonylurea
Trial: 34804608
Drug: Sulphonylurea(s) monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea(s) monotherapy
Trial: 34804848
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg weekly
Trial: 34805632
Drug: AZD5718 (5-Lipoxygenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5718 (5-Lipoxygenase Activating Protein Inhibitor)
Trial: 34805632
Drug: AZD5718 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5718 plus dapagliflozin (10 mg/d)
Trial: 34805723
Drug: Whole-grain diet
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain diet (50 g/1000 kcal per day)
Trial: 34806137
Drug: Dupilumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab plus topical corticosteroids (TCS)
Trial: 34806163
Drug: GELAD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GELAD chemotherapy regimen (gemcitabine 1.0 g/m²)
Trial: 34808524
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of six molecularly targeted agents and a PD-L1 antagonist
Trial: 34808624
Drug: rhythmic speech-language
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhythmic speech-language therapy (rSLT)
Trial: 34808624
Drug: no-therapy (NT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-therapy (NT)
Trial: 34809507
Drug: Apixaban discontinuation
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban discontinuation prior to surgery
Trial: 34809974
Drug: Total folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total folate intake up to 1,200 μg/d
Trial: 34809974
Drug: Supplemental folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental folate intake up to 800 μg/d
Trial: 34813486
Drug: VR treatment
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR treatment (self-guided, mobile app-based VR CBT)
Trial: 34813506
Drug: TIL infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIL infusion products
Trial: 34813910
Drug: Once-weekly exenatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly exenatide (EQW) plus usual care
Trial: 37639820
Drug: Oral targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral targeted therapy
Trial: 34814935
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafamostat mesilate (0.1 to 0.2 mg/kg/h, 2.4 to 4.8 mg/kg/day) with standard therapy
Trial: 34814935
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (lopinavir/ritonavir, hydroxychloroquine, oxygen therapy, non-invasive and invasive ventilator, antibiotic therapy, renal-replacement therapy, ECMO)
Trial: 34816294
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg methylprednisolone and 5 mg/day ruxolitinib
Trial: 34817837
Drug: 2020 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2020 treatment of benign/precursors diseases
Trial: 34817837
Drug: 2020 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2020 treatment of neuroendocrine tumors
Trial: 34818478
Drug: Belzutifan (MK-6482)
RxNorm normalized name: belzutifan
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan (MK-6482) 120 mg daily
Trial: 34818965
Drug: Elotuzumab in
RxNorm normalized name: elotuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone
Trial: 34818965
Drug: Elotuzumab in
RxNorm normalized name: elotuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab in combination with pomalidomide, carfilzomide, and low-dose dexamethasone
Trial: 34819039
Drug: Entinostat monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat monotherapy (3 mg/qw, 5 mg/qw, or 10 mg/q2w)
Trial: 34819039
Drug: Entinostat combined
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat combined with exemestane (5 mg/qw + 25 mg/qd)
Trial: 34819039
Drug: Entinostat monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat monotherapy and combined entinostat/exemestane
Trial: 34819116
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment in addition to treatment as usual (TAU) - 5 sessions of 30 minutes each, using soft specific palpatory techniques on the diaphragm, digestive system, and cervical region.
Trial: 34819116
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) only.
Trial: 34819138
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of autologous adipose tissue (AT) around the anal fistula tract
Trial: 34820133
Drug: Cisplatin therapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin therapy
Trial: 34822128
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of treatment
Trial: 34823566
Drug: Hearing implants
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hearing implants
Trial: 34824054
Drug: Oral corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroid (OCS) use
Trial: 34824109
Drug: Clinical pharmacists
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacists integrated into the ED team providing pharmaceutical care services such as medication reconciliation, review and/or counselling.